42 results about "Genistein" patented technology

The invention discloses a method for increasing the content of genistin and genistein in flemingia philippinensis by using potassium. Culturing the flemingia philippinensis tissue culture seedlings in a propagation culture medium, and subculturing to obtain flemingia philippinensis stem segments with leaves; taking stems of the flemingia philippinensis, and culturing the stems in a rooting culture medium to obtain the flemingia philippinensis with the content of genistin and genistein increased; wherein the propagation culture medium is prepared from MS (Murashige and Skoog), 6-benzyladenine, indoleacetic acid and kinetin; the rooting culture medium comprises KNO3, MS (Murashige and Skoog) and naphthylacetic acid, and the MS does not contain KNO3. According to the method for increasing the content of genistin and genistein in the flemingia philippinensis by using potassium, accumulation of active ingredients of genistin and genistein at the root of the flemingia philippinensis is adjusted by adding exogenous potassium ions, so that the utilization rate of the flemingia philippinensis is increased, and the problem of resource shortage of the flemingia philippinensis is relieved.

The inventors have found that quercetin and genistein, individually, suppress the expression of some aging-related genes while promoting the expression of other aging-related genes. Therefore, the main objective was to maintain the repressive effect on some aging-related genes that quercetin, genistein, and their glycosides may have, while suppressing the effect of promoting the expression of other aging-related genes. [Solution] The above problem can be solved by combining two or three components selected from the group consisting of component (i): quercetin and / or its glycosides, component (ii): genistein and / or its glycosides, and component (iii): nobiletin and / or its glycosides.

The invention relates to a recombinant microbial strain for de novo synthesis of gardenin B and application of the recombinant microbial strain in production of polymethoxylated flavone compounds, and belongs to a cross technology of synthetic biology and organic synthetic chemistry. The invention designs and constructs a heterozygous gardenin B biosynthesis pathway, and obtains a microbial strain for synthesizing gardenin B from the beginning. By screening F8H and redox partner types and regulating and controlling subcellular localization, an F8H-redox partner combination with optimal space and type is determined, and an engineering strain of which the gardenin B yield is greatly improved is obtained. The efficient synthesis method of the polymethoxylated flavonoids is established by selecting recombinant microorganisms for synthesizing gardenin B from de novo to perform co-culture fermentation or chemical conversion of fermentation products.

The invention relates to the technical field of food biology, in particular to a high-activity fermented astragalus mongholicus and red date compound for improving myocardial function, which is prepared by taking Xinjiang Qiang red dates and astragalus mongholicus as main raw materials and matching cellulase, pectinase, beta-glucanase and hydroxypropyl-beta-cyclodextrin. In the preparation process, gradient freezing-microwave pretreatment and ternary composite enzymolysis synergistic wall breaking are adopted, quaternary strains of bifidobacterium longum, bacillus subtilis, saccharomyces cerevisiae and lactobacillus plantarum are compounded, adenosine concentration response type staged solid-state fermentation is performed, and microcapsule embedding stabilizing treatment is performed to obtain the product. The content of cAMP in the product is greater than or equal to 13.0 mu g / g, and the content of calycosin-7-glucoside in astragalus membranaceus is greater than or equal to 1.9 mg / g. The compound can be used for preparing myocardial ischemia pretreatment health-care food and a pharmaceutical composition for adjuvant therapy in the myocardial infarction recovery period, and the dosage forms comprise chewable tablets, oral liquid, capsules and the like.

The inventors' primary objective was to provide a technology that suppresses inflammation, particularly in aging tissues. [Solution] The above problem can be solved by a composition containing at least one selected from the group consisting of genistein, quercetin, fisetin, nobiletin, kaempferol, apigenin, and naringenin, and glycosides thereof.

The application discloses genistein with CD38 inhibitory activity and a preparation method and application thereof. The preparation method comprises the following steps: crushing dried purslane, adding water and a composite enzyme into the obtained purslane powder to perform enzymolysis; adding ethanol into the obtained enzymolysis liquid to perform ultrasonic-assisted extraction, decompression concentration and organic solvent extraction; performing macroporous adsorption resin separation and elution on the obtained extraction liquid, collecting the eluate; performing gel column chromatography separation and liquid chromatography purification on the obtained eluate, and drying to obtain genistein. The preparation method is simple, the prepared genistein has high purity, and the highest purity can reach 99.05%; and the prepared genistein has good CD38 inhibitory activity, and opens up a new use of purslane genistein. + horizontal promotion of medicines, health products and food.

The invention discloses a high-yield beta-glucosidase strain and application of the high-yield beta-glucosidase strain in efficient conversion of genistin, and belongs to the technical field of microbial fermentation and enzyme engineering. In order to solve the problems of low enzyme activity and low conversion efficiency of a beta-glucosidase production strain in the prior art, the invention provides the lactobacillus mucus DQ7-1 of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.36230, and the lactobacillus mucus DQ7-1 has the advantages that the lactobacillus mucus DQ7-1 has the preservation number of CGMCC No.36230; the strain is obtained through natural fermentation with soybean whey as a raw material in combination with aesculin color development and p-nitrobenzene-beta-D-glucopyranoside quantitative enzyme activity screening methods, and the beta-glucosaccharase activity of the strain is remarkably higher than that of common lactic acid bacteria. The strain is mainly used for catalyzing efficient conversion of soybean isoflavone glycoside, especially genistin, to genistein in the aglycone form, and has important application value in the fields of functional food, medicine and feed.

The invention provides application of dragon's blood and active ingredients thereof in preparation of a medicine for treating heart failure, and belongs to the technical field of biological medicine. It is found for the first time that the dragon's blood can significantly improve the heart function of a heart failure model animal, reduce the level of a heart failure marker and relieve cardiac hypertrophy, cardiac pulmonary edema, myocarditis infiltration and fibrosis; core active components such as genistein and 3-hydroxycinnamic acid are screened and verified, wherein the genistein can reproduce the overall treatment effect of the dragon's blood. The invention also discloses that the core action mechanism of the composition is to promote macrophage VEGFC secretion, increase heart lymphatic vessel density and promote lymphatic vessel neogenesis, and a brand new natural drug candidate scheme and an intervention strategy are provided for heart failure treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to application of genistein to preparation of an anti-colorectal cancer medicine for inhibiting LINC00355 expression. According to the present invention, the genistein is adopted as the LINC00355 expression inhibitor so as to effectively inhibit the expression of the LINC00355, such that the adsorption effect of the LINC00355 on the miR-150 is relieved, the expression of the miR-150 is up-regulated, the expression of the SGK1 is further inhibited by the miR-150, the activation of the downstream EGFR / PI3K / Akt and MAPK signal channels is finally inhibited, and the activity of the downstream EGFR / PI3K / Akt and MAPK signal channels is inhibited; and inhibition of colorectal cancer cell proliferation, inhibition of colorectal cancer cell cycle G0 / G1 phase, induction of colorectal cancer cell apoptosis and inhibition of colorectal cancer cell migration and invasion ability are realized, so that a better anti-colorectal cancer treatment effect is achieved.

The invention discloses a method for preparing oligomeric genistein by oxidative conversion of genistein with laccase. According to the method, the coprinus cinerea laccase Lcc5 is used for preparing the oligomeric genistein, so that the condition for preparing the product is optimized, the conversion rate is increased to about 92%, and the product with higher polymerization degree is obtained. The antioxidant activity, the enzyme inhibition activity, the anti-amyloid aggregation activity and the antibacterial activity of the obtained conversion product are remarkably improved compared with those of monomer genistein. The enzyme has potential application value in oxidative conversion of genistein and other isoflavones to improve the biological value of genistein and other isoflavones.

The invention discloses an antibacterial polyurethane medical catheter material and a preparation method thereof, and relates to the technical field of polyurethane materials. When the antibacterial polyurethane medical catheter material is prepared, genistein and zinc acetate react to prepare a genistein complex; the preparation method comprises the following steps: sequentially treating boron nitride with sodium hydroxide and kh550 to prepare aminated boron nitride; reacting the aminated boron nitride with a phosphorus-containing flame retardant to prepare functionalized boron nitride; the preparation method comprises the following steps: reacting 2-amino-2-methyl-1, 3-propylene glycol with 4-pyridylaldehyde and 1-bromohexane in sequence to prepare a pyridinium salt monomer; the preparation method comprises the following steps: polymerizing polytetrahydrofuran and diphenylmethane diisocyanate, and carrying out chain extension on a pyridinium monomer to prepare polyurethane; the preparation method comprises the following steps: uniformly mixing polyurethane, a genistein complex and functionalized boron nitride to prepare an antibacterial polyurethane medical catheter material; the antibacterial polyurethane medical catheter material prepared by the preparation method disclosed by the invention has good antibacterial and flame-retardant effects.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

This invention discloses an analytical method for the application of wolfberry in the preparation of foods and drugs for rheumatoid arthritis. First, 36 active ingredients and 201 drug targets of wolfberry were obtained through a traditional Chinese medicine systems pharmacology database and analysis platform. Then, 536 targets for rheumatoid arthritis were predicted using Gene Cards and TTD databases, and 55 intersection targets were obtained through Venn diagram analysis. An intersection target network diagram and a "drug-ingredient-target-disease" network diagram were constructed. Topological analysis screened out four core targets: IL1B, JUN, IL6, and TNF, and five core ingredients. Molecular docking results showed that quercetin, genistein, β-sitosterol, stigmasterol, and lycopene strongly bound to the four core targets. This invention provides a theoretical reference for the development of drugs for the treatment of rheumatoid arthritis.

The invention discloses a method for increasing the content of genistein in flemingia philippinensis by using nitrogen. Culturing the flemingia philippinensis tissue culture seedlings in a propagation culture medium, and subculturing to obtain flemingia philippinensis stem segments with leaves; taking stems of the flemingia philippinensis, and culturing the stems in a rooting culture medium to obtain the flemingia philippinensis with increased genistein content; wherein the propagation culture medium is prepared from MS (Murashige and Skoog), 6-benzyladenine, indoleacetic acid and kinetin; the rooting medium comprises NH4NO3, MS (Murashige and Skoog) and naphthylacetic acid, and the MS does not contain NH4NO3. According to the method for increasing the content of genistein in the flemingia philippinensis by using nitrogen, accumulation of the active ingredient genistein at the root of the flemingia philippinensis is adjusted by adding exogenous nitrogen ions, so that the utilization rate of the flemingia philippinensis is increased, and the problem of resource shortage of the flemingia philippinensis is relieved.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of genistein to preparation of a medicine for improving brain cognitive impairment caused by low pressure and low oxygen. Research results show that low pressure and low oxygen can cause brain cognitive dysfunction of mice. The genistein can relieve brain dysfunction after low-pressure and low-oxygen exposure of mice by inhibiting neuroinflammation, recovering hippocampal neurological functions and improving hippocampal oxidative aggression. The invention provides a novel therapy for brain cognitive impairment caused by low pressure and low oxygen in various leguminous plant components, which is mainly derived from soy isoflavone by verifying a pharmaceutical active component, namely genistein.

The invention discloses an acacetin and piperazine eutectic, a preparation method, a composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention discloses an eutectic substance formed by acacetin and piperazine, and the molecular formula of the eutectic substance is (C16H12O5). (C4H10N2). The invention relates to a preparation method of a cocrystal of acacetin and piperazine. The acacetin and piperazine eutectic is used as an active ingredient of a medicine and is applied to preparation of medicines for resisting oxidation, resisting inflammation, resisting viruses, resisting tumors, resisting rheumatism, easing pain, protecting the liver, regulating immunity, treating osteoporosis and treating cardiovascular and cerebrovascular diseases.

The application discloses a method for improving the proportion of genistein in soybean isoflavone glycosides through directional fermentation. Lactobacillus sp. The method is characterized in that Lactobacillus (RS-03027) is used for fermentation after induced pre-culture, and the substrate is fed in batches, so that high selective conversion of isoflavone glycosides to genistein is realized. The strain has high beta-glucosidase activity related conversion capacity, has been preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.21302. The process realizes high accumulation and high selective enrichment of the target product, effectively inhibits non-target aglycone, and has industrial amplification application potential.

The present disclosure addresses the problem of providing a composition that contains 5-hydroxyequol and that can be used in a new application. The present disclosure also addresses another problem of providing a method for extending healthy life expectancy, the method comprising bringing 5-hydroxyequol into contact with a subject.　The present disclosure provides a composition for extending healthy life expectancy, the composition containing 5-hydroxyequol. Also provided is a method for producing a composition containing 5-hydroxyequol, the method comprising producing 5-hydroxyequol from genistein through fermentation. The present disclosure also provides a method for extending healthy life expectancy, the method comprising bringing 5-hydroxyequol into contact with a subject.

The invention provides genistein compound essential oil as well as a preparation method and application thereof, and the genistein compound essential oil comprises the following components in parts by mass: 40%-45% of genistein essential oil, 5%-10% of laurel essential oil, 5%-10% of salvia officinalis, 5%-10% of lavender oil, 5%-8% of sweet orange essential oil, 5%-10% of jasmine essential oil and 5%-8% of vetiver (frankincense) essential oil. And adding the basic carrier oil to 100%. The product disclosed by the invention is applied to aromatherapy and aromatherapy products. The natural genistein compound essential oil provided by the invention is beneficial to improving mood and increasing pleasure and happiness by virtue of the fresh wood fragrance, and for climacteric women, the natural genistein compound essential oil is possibly beneficial to relieving depression and low mood, and relieving anxiety and tension; meanwhile, the dye wood essential oil has relaxing and calming effects and is used for improving the sleep quality of women.

The invention discloses an acacetin and zolpidem eutectic crystal, a preparation method, a composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention discloses an eutectic substance formed by acacetin and zolpidem, and the molecular formula of the eutectic substance is (C16H12O5). (C19H21N3O), the invention relates to a preparation method of a cocrystal of acacetin and zolpidem. The acacetin and zolpidem eutectic crystal is used as an active ingredient of a medicine and is applied to preparation of medicines for resisting oxidation, resisting inflammation, resisting viruses, resisting tumors, resisting rheumatism, easing pain, protecting the liver, regulating immunity, treating osteoporosis and treating cardiovascular and cerebrovascular diseases.

The application belongs to the technical field of medicine, and discloses application of genistein in preparation of medicine for resisting Mycobacterium tuberculosis. The application discloses application of genistein or a pharmaceutically acceptable derivative thereof in inhibition of Mycobacterium tuberculosis or preparation of products for resisting Mycobacterium tuberculosis. Experiments show that the MIC of genistein to M. tb H37Rv ΔleuΔpan and M. tb M. tb M. tb M. tb M. tb H37Ra is 0.03 mg / mL, and under the action of 30 μg / mL genistein, the minimum inhibitory concentration of a rifampicin-resistant strain is reduced from 50 μg / mL to 6.25 μg / mL, which greatly improves the sensitivity of the drug-resistant strain to rifampicin. Therefore, genistein can be used in preparation of medicine for resisting Mycobacterium tuberculosis or resisting tuberculosis alone, and can also be used as an auxiliary medicine for other anti-tuberculosis medicines for combined use, that is, the types of anti-tuberculosis medicines are widened and the course of treatment of tuberculosis is expected to be shortened.

The invention discloses a construction method and application of a rodent model for male adult offspring fertility reduction caused by prednisone exposure during pregnancy. The fertility of male adult offspring is reduced due to prednisone exposure during pregnancy, rodents are subjected to gavage with prednisone in the whole pregnancy process, and the offspring is normally fed for 12 weeks after being born. Male offspring testis or sperms which are 20 days after pregnancy and 12 weeks after birth are obtained, and fetal testis dysplasia and adult fertility reduction are proved. Based on the animal model, it is proved that male adult offspring fertility reduction caused by prednisone exposure during pregnancy can be reversed when genistein is given to pregnant rats at the same time during pregnancy. The animal model established by the invention has the characteristics of novelty, reliability, simplicity and convenience, and is of great significance to elucidating a fertility reduction mechanism of male offspring caused by prednisone exposure during pregnancy and exploring an early prevention and treatment technology of the male offspring.

The invention belongs to the technical field of biological medicines, and particularly relates to application and a method of flavonoid compounds in enhancing nucleic acid molecule delivery efficiency of lipid nanoparticles. The invention aims to solve the problems of limited LNP in-vivo and in-vitro delivery efficiency, toxic risk and the like. According to the invention, seven low-toxicity and biocompatible natural compounds such as genistein, glabridin, rhoifolin, luteolin, hesperetin, galangin or pinocembrin are used as an LNP high-efficiency expression enhancer, the compounds and target cells are co-incubated, and then LNP containing nucleic acid molecules is added. According to the scheme, the LNP-mediated gene expression efficiency can be remarkably improved, the cytotoxicity can be reduced, and in-vivo experiments prove that LNP biological distribution can be optimized, target tissue expression can be enhanced, and collaborative optimization of LNP safety and high efficiency is achieved.

This invention relates to an integrative plasmid for multicopy iteration of the Saccharomyces cerevisiae genome and its application, belonging to the field of biotechnology. This invention first constructs a multicopy integration vector, using Ty1, Ty2, Ty3, and Ty4 as multicopy integration target sites to construct four integrative plasmids. Each plasmid carries a fluorescent protein reporter gene (mScarlet-I or GFP) and an antibiotic resistance marker gene (such as hygromycin or genistein) to enable visualization and screening of the integration site. Applied to the preparation of nervonic acid, it achieves continuous editing without the need for monoclonal isolation. The strain obtained in the fourth round was screened by plate fermentation and verified in a 3 L fermenter, yielding a high nervonic acid production strain.

The main purpose of the present inventors is to provide a technique for suppressing inflammation, in particular, in aging tissues within the oral cavity.　The present inventors have found that an oral composition containing at least one selected from the group consisting of β-glycyrrhetinic acid, glycyrrhizic acid, ascorbic acid, tocopherol nicotinate, tocopherol acetate, pyridoxine, cobalamin, retinol, retinol acetate, riboflavin, phylloquinone, calciferol, anthraquinone, menaquinone-4, and L-aspartic acid, and chemically acceptable salts thereof, quercetin, genistein, fisetin, nobiletin, kaempferol, apigenin, and naringenin, and glycosides thereof, and methyl hesperidin can suppress inflammation, in particular, in aging tissues within the oral cavity.

The application discloses a preparation method for separating and extracting genistein from carob pods, and specifically comprises the following steps: rough powder of carob pods is extracted with 80-95% and 60-80% ethanol successively to obtain an extract, and the extract is adsorbed by macroporous adsorption resin D101 to obtain non-sugar small molecules; the non-sugar small molecules are successively extracted by petroleum ether and ethyl acetate, and are separated and purified by silica gel column, ODS, Sephadex LH-20 column chromatography and semi-preparative liquid phase to obtain high-purity genistein; and the high-purity genistein has the effect of regulating estrogen and improving menopausal syndrome.

The invention discloses a UHPLC-MS / MS (Ultra High Performance Liquid Chromatography-Mass Spectrometry / Mass Spectrometry)-based multi-component content determination method for a compound radix scutellariae throat-clearing capsule, which is characterized in that a multi-component simultaneous quantitative analysis method is established by adopting a UHPLC-MS / MS technology, and the quality of the compound radix scutellariae throat-clearing capsule is evaluated from the quantitative aspect. 21 components including p-hydroxybenzaldehyde, vanillin, caffeic acid, syringaldehyde, citric acid, tanshinol, chrysin, baicalein, genistein, quercetin, chlorogenic acid, neochlorogenic acid, rosmarinic acid, harpagide, puerarin, apigenin-7-O-beta-D-glucoside, baicalin, oleanolic acid, scutellarin, glycyrrhetinic acid and harpagoside are selected as quantitative indexes; and determining the content of the compound radix scutellariae throat-clearing capsule. According to the method, the contents of 21 components in the compound radix scutellariae throat-clearing capsule can be accurately measured at the same time within 14 min, and the method has good precision and stability.

The invention belongs to the field of traditional Chinese medicine preparation, and relates to application of biflavone compounds isochamaejasmine and genkwanol A in preparation of anti-complement drugs. According to the present invention, the biflavone compounds such as the isochamaejasme and the genkwanol A are extracted from the ethyl acetate extraction part of the ethanol extract of the dried root of Stellera tianshanica plant Stellera tianshanica Pod. The in-vitro anti-complement activity evaluation experiment results prove that the biflavone compounds such as the isochamaejasme and the genkwanol A have strong inhibition effects on the classical pathway and the alternative pathway of the complement system, wherein the stellera tianshanica and the genkwanol A are extracted from the ethyl acetate extraction part of the ethanol extract of the dried root of Stellera tianshanica Pod. The biflavone compound isochamaejasmine and genkwanol A can be further used for preparing medicines for treating complement related diseases, and the complement related diseases comprise systemic lupus erythematosus, rheumatoid arthritis or acute respiratory distress syndrome.

The application provides a modified monascus exopolysaccharide and an application thereof, and the yield of the monascus exopolysaccharide is effectively improved by adding genistein in a fermentation medium, and the modified monascus exopolysaccharide with high biological activity is generated; the monascus exopolysaccharide provided by the application effectively improves the osteogenic differentiation effect of mesenchymal stem cells, and provides a new treatment drug and a treatment approach for the treatment of osteoporosis; the preparation method provided by the application is simple, green, environment-friendly, short in period, and low in cost and high in efficiency, and is favorable for realizing high-value utilization of monascus resources in China.